Somewhat Positive Press Coverage Somewhat Unlikely to Impact China Biologic Products (CBPO) Stock Price
News coverage about China Biologic Products (NASDAQ:CBPO) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. China Biologic Products earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.429689989455 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Applying technical analysis concepts on China Biologic Products Holdings, Inc. (CBPO) – Wall Street Morning (wallstreetmorning.com)
- China Biologic Products (CBPO) Upgraded to “Sell” by BidaskClub (americanbankingnews.com)
- China Biologic Products (CBPO) and Galmed Pharmaceuticals (GLMD) Head to Head Contrast (americanbankingnews.com)
- China Biologic Products’ (CBPO) “Buy” Rating Reiterated at Jefferies Group (americanbankingnews.com)
Several equities research analysts have recently weighed in on CBPO shares. Zacks Investment Research cut China Biologic Products from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. BidaskClub cut China Biologic Products from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Deutsche Bank set a $105.00 price target on China Biologic Products and gave the company a “buy” rating in a research note on Friday, March 2nd. TheStreet cut China Biologic Products from a “b-” rating to a “c+” rating in a research note on Thursday, March 1st. Finally, Jefferies Group reissued a “buy” rating and issued a $97.00 price target on shares of China Biologic Products in a research note on Thursday, March 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. China Biologic Products has a consensus rating of “Hold” and a consensus price target of $101.00.
China Biologic Products (NASDAQ:CBPO) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.89 by $0.01. China Biologic Products had a return on equity of 21.30% and a net margin of 18.34%. The business had revenue of $90.10 million during the quarter, compared to analysts’ expectations of $85.15 million. During the same quarter last year, the firm posted $0.95 earnings per share. The firm’s revenue was up 16.1% on a year-over-year basis. equities research analysts anticipate that China Biologic Products will post 5.09 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/03/21/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-china-biologic-products-cbpo-stock-price-2.html.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.